对高癌症死亡率及传统癌症治疗的不足引起了广泛关注。免疫治疗是一种高效低副作用的新型肿瘤学治疗方法，是临床肿瘤学治疗的一个革命性方向。然而，其临床疗效不均。基于对程序性细胞死亡（PCD）的重新定义和重新分类（分为坏死样细胞死亡、铁死、焦亡和自噬），纳米医学引发的PCD在癌症治疗中的作用也受到了重视。临床和临床前研究已开始将PCD与免疫治疗结合起来。本文介绍了近期肿瘤免疫治疗研究的进展，概述了纳米医学引发的PCD在肿瘤治疗中的参与方式，并回顾了纳米医学引发的PCD如何改善免疫治疗的局限性以增强肿瘤免疫治疗。还提出了纳米医学介导的PCD肿瘤治疗和肿瘤免疫治疗的未来发展。重要的科学概念概述了纳米医学引发的PCD是一种有前途的肿瘤免疫治疗方法。纳米医学增加了肿瘤部位的穿透能力和靶向能力，纳米医学介导的PCD激活可以刺激强大的抗肿瘤免疫反应，对肿瘤的免疫治疗有很好的贡献。版权所有 © 2023 Elsevier B.V. 的制作和托管。

There has been widespread concern about the high cancer mortality rate and the shortcomings of conventional cancer treatments. Immunotherapy is a novel oncology therapy with high efficiency and low side effects, which is a revolutionary direction for clinical oncology treatment. However, its clinical effectiveness is uneven. Based on the redefinition and reclassification of programmed cell death (PCD) (divided into necroptosis, ferroptosis, pyroptosis, and autophagy), the role of nanomedicine-induced PCD in cancer therapy has also received significant attention. Clinical and preclinical studies have begun to combine PCD with immunotherapy.In this article, we present recent research in tumor immunotherapy, provide an overview of how nanomedicine-induced PCD is involved in tumor therapy, and review how nanomedicine-induced PCD can improve the limitations of immunotherapy to enhance tumor immunotherapy. The future development of nanomedicine-mediated PCD tumor therapy and tumor immunotherapy is also proposed Key scientific concepts of overview Nanomedicine-induced PCD is a prospective method of tumor immunotherapy. Nanomedicines increase tumor site penetration and targeting ability, and nanomedicine-mediated PCD activation can stimulate powerful anti-tumor immune effects, which has a good contribution to immunotherapy of tumors.Copyright © 2023. Production and hosting by Elsevier B.V.